Download PDF
Thromb Haemost 1987; 57(01): 102-105
DOI: 10.1055/s-0038-1651071
Original Articles
Schattauer GmbH Stuttgart

Immunoaffinity Purification of Factor VIII Complex

V S Hornsey
The Edinburgh and South-East Scotland Blood Transfusion Service, Royal Infirmary, University of Edinburgh Medical School, Edinburgh, Scotland
,
B D Griffin
*   The Scottish National Blood Transfusion Service Headquarters Unit Laboratory, University of Edinburgh Medical School, Edinburgh, Scotland
,
D S Pepper
*   The Scottish National Blood Transfusion Service Headquarters Unit Laboratory, University of Edinburgh Medical School, Edinburgh, Scotland
,
L R Micklem
**   The Department of Surgery, University of Edinburgh Medical School, Edinburgh, Scotland
,
C V Prowse
The Edinburgh and South-East Scotland Blood Transfusion Service, Royal Infirmary, University of Edinburgh Medical School, Edinburgh, Scotland
› Author Affiliations
Further Information

Publication History

Received 25 August 1986

Accepted after revision 05 December 1986

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Murine monoclonal antibodies to human von Willebrand factor (vWf) were immobilised on Sephacryl S-1000. Various solutes were screened for their ability to elute 125 I-vWf from the immobilised antibodies. The most effective solutions were then tested to determine which allowed retention of factor VIII procoagulant activity (VIII: C) and activity of vWf measured by platelet aggregation in the presence of ristocetin (Ristocetin cofactor activity R.cof.). Finally, F VIII complex was purified from both plasma and cryoprecipitate by immunoaffinity chromatography under the selected conditions. The product had a specific activity of 45 units of VIII: C per mg of protein and 60 units of R. cof. per mg representing a 4000-fold purification from plasma. The fibrinogen and fibroneetin content were each less than 4% of the total protein with vWf accounting for 60% of the total protein in the final product. Multimer analysis of the product showed a similar pattern to normal plasma and contamination by murine monoclonal antibody was less than 300 ng per mg of protein. A novel product is thus obtained containing both clinically relevant VIII :C and R. cof. in a single vial whilst using only one specific monoclonal antibody.

Keywords

Factor VIII - Monoclonal antibody - Affinity chromatography
 

  • References

  • 1 Smith JK, Bidwell E. Therapeutic materials used in the treatment of coagulation defects. Clinics in Haematol 1979; 8: 183-206
    PubMedGoogle Scholar
  • 2 Foster PR, Dickson AJ, McQuillan TA, Dickson IH, Keddie S, Watt JG. Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII. Vox Sang 1982; 42: 180-189
    CrossrefPubMedGoogle Scholar
  • 3 Austen D EG. The chromatographic separation of factor VIII on aminohexyl Sepharose. Br J Haematol 1979; 43: 669-674
    CrossrefPubMedGoogle Scholar
  • 4 McPherson J, Soberano ME, MacDonald C, Zucker MB. Evidence that von Willebrand factor is not required for the clotting of plasma in the presence of platelets and kaolin (Hardisty-Hutton Test). Thromb Haemostas 1984; 51: 272-274
    PubMedGoogle Scholar
  • 5 Zucker MB, Soberano ME, Johnson AJ, Fulton AJ, Kowalski S, Adler M. The in vitro association of antihemophilic factor and von Willebrand factor. Thromb Haemostas 1983; 49: 37-41
    PubMedGoogle Scholar
  • 6 Fulcher CA, Zimmerman TS. Characterisation of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 72: 1648-1652
    PubMedGoogle Scholar
  • 7 Homsey V, Micklem LR, McCann MC, James K, Dawes J, McClelland D BL, Prowse CV. Enhancement of factor VIII von Willebrand factor ristocetin cofactor activity by monoclonal antibodies. Thromb Haemostas 1985; 54: 510-514
    PubMedGoogle Scholar
  • 8 Wright JF, Hunter WM. A convenient replacement for cyanogen bromide-activated solid phases in immunoradiometric assays. J Immunol Methods 1982; 48: 311-325
    CrossrefPubMedGoogle Scholar
  • 9 Kohn J, Wilchek M. A new approach (cyano-transfer) for cyanogen bromide activation of Sepharose at neutral pH which yields activated resins free of interfering nitrogen derivatives. Biochem Biophys Res Comm 1982; 107: 878-884
    CrossrefPubMedGoogle Scholar
  • 10 Prowse CV, McGill A. Evaluation of the “Mason” (continuous-thawsiphon) method for cryoprecipitate production. Vox Sang 1979; 37: 235-243
    PubMedGoogle Scholar
  • 11 Laemmli VK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 12 Gomall AG, Bardswill CJ, David MM. Determination of serum proteins by means of the Biuret reaction. J Biol Chem 1949; 177: 751-766
    PubMedGoogle Scholar
  • 13 Prowse CV, Homsey V, McKay G, Waterston Y. Room temperature microtray chromogenic assay of factor VIII: C. Vox Sang 1986; 50: 21-25
    CrossrefPubMedGoogle Scholar
  • 14 Griffin BD, Micklem LR, McCann MC, James K, Pepper DS. The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII. Thromb Haemostas 1986; 55: 40-46
    PubMedGoogle Scholar
  • 15 Hunter WM. Simplified solid phase radioimmunoassay without centrifugation. Acta Endocrinol 1977; 85 Suppl (212) 463
    PubMedGoogle Scholar
  • 16 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29 Suppl (124) 21-37
    CrossrefPubMedGoogle Scholar
  • 17 Robinson DR, Jencks WP. The effect of compounds of the ureaguanidinium class on the activity coefficient of acetyltetraglycine ethyl ester and related compounds. J Am Chem Soc 1965; 87: 2462-2470
    CrossrefPubMedGoogle Scholar
  • 18 Harris RB, Newman J, Johnson AJ. Differentiation of antihemophilic factor (AHF) and von Willebrand factor (vWf) by their interaction with urea and selected amino acids. Thromb Res 1977; 11: 773-783
    CrossrefPubMedGoogle Scholar
  • 19 Mikaelsson ME, Forsman N, Oswaldsson UM. Human factor VIII: A calcium-linked protein complex. Blood 1983; 62: 1006-1015
    PubMedGoogle Scholar
  • 20 Rock GA, Cruikshank WH, Tackaberry ES, Ganz PR, Palmer DS. Stability of VIII: C in piasma: the dependence on protease activity and calcium. Thromb Res 1983; 29: 521-535
    CrossrefPubMedGoogle Scholar
  • 21 Zimmermann TS, Fulcher CA. Ultrapurification of factor VIII using monoclonal antibodies. US Patent 1982; No.4, 361, 509
    PubMedGoogle Scholar
  • 22 Tuddenham E GD, Trabold NC, Collins JA, Hoyer LW. The properties of factor VIII coagulant activity prepared by immuno-adsorbent chromatography. J Lab Clin Med 1979; 93: 40-53
    PubMedGoogle Scholar
  • 23 Rotblat F, O’Brien DP, O’Brien FJ, Goodall AH, Tuddenham EG. Purification of human factor VIII: C and its characterisation by western blotting using monoclonal antibodies. Biochem 1985; 24: 4294-4300
    CrossrefPubMedGoogle Scholar
  • 24 Jaffers GJ, Fuller TC, Cosimi AB-Bussell PS, Winn HJ, Colvin RB. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT 3 arising despite intense immunosuppression. Transplantation 1986; 41: 572-578
    CrossrefPubMedGoogle Scholar
  • 25 Enayat MS, Hill F GH. Analysis of the complexity of the multimeric structure of factor VIII related antigen/von Willebrand protein using a modified electrophoretic technique. J Clin Pathol 1983; 36: 915-919
    CrossrefPubMedGoogle Scholar